Review of epidemiology and management of atrial fibrillation in developing countries

Nguyen, Tu Ngoc; Hilmer, Sarah N.; Cumming, Robert G.

doi:10.1016/j.ijcard.2013.01.184

Cited by 114 publications

(103 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, several population-based studies and registries have provided information on the incidence, prevalence, and outcome of AF population [6,7,[10][11][12]. However, there are no data regarding the characteristics of AF patients in Poland.…”

Section: Discussionmentioning

confidence: 99%

Management of patients with valvular and non-valvular atrial fibrillation in Poland: Results from Reference Cardiology University Center

et al. 2015

View full text Add to dashboard Cite

Background: Information on epidemiology of atrial fibrillation (AF) in Middle European 001). Patients with valvular AF had more often permanent AF (p < 0.004). Valvular AF patients were more often prescribed antithrombotic therapy (p = 0.001). The in-hospital mortality did not differ between patients with valvular and non-valvular AF (p = 0.3). In multivariate logistic regression, odds of in-hospital death were higher for patients > 75 years old (OR = 6.26, p = 0.001,) and with ejection fraction < 35% (OR = 5.25, p < 0.001, (Cardiol J 2015; 22, 3: 296-305)

show abstract

Section: Discussionmentioning

confidence: 99%

Management of patients with valvular and non-valvular atrial fibrillation in Poland: Results from Reference Cardiology University Center

et al. 2015

View full text Add to dashboard Cite

show abstract

“…6–7,6–18 The rate of AF is different among different ethnic populations such as Indo‐Asians 19 and African Americans 3,20–21 and varies considerably in different geographical areas of the globe 2,22–23 with wide variation not only in the prevalence of AF 2,22–23 but also in management and outcomes. 2,22–23 Of note, studies that used mostly hospitalization‐based diagnoses of AF showed higher rates of AF 22–23 and stroke 22 as compared with community studies. Studies that include patients diagnosed with atrial fibrillation at the hospital setting as well as those diagnosed in the community may provide more comprehensive and complete data of the distribution, management, and outcomes of this condition.…”

Section: Introductionmentioning

confidence: 99%

Prospective National Study of the Prevalence, Incidence, Management and Outcome of a Large Contemporary Cohort of Patients With Incident Non‐Valvular Atrial Fibrillation

Haim

Hoshen

Reges

et al. 2015

JAHA

211

119

View full text Add to dashboard Cite

BackgroundThere are few studies of atrial fibrillation (AF) outside of North America or Europe. The aim of the present study was to assess the prevalence, incidence, management and outcomes of patients with new atrial fibrillation, in a large contemporary cohort (2004–2012) of adult patients.Methods and ResultsThe Clalit Health Services (CHS) computerized database of 2 420 000 adults, includes data of community clinic visits, hospital discharge records, medical diagnoses, medications, medical interventions, and laboratory test results. The prevalence of AF on January 1, 2004 was 71 644 (3%). Prevalence and incidence of AF increased with age and was higher in men versus women. During the study period (2004–2012) 98 811 patients developed new non‐valvular AF (mean age −72, 50% women, 46% with cardiovascular disease, 6% with prior stroke). The rate of persistent warfarin use (dispensed for >3 months in a calendar year) was low (25.7%) and it increased with increasing stroke risk score. Individual Time in Therapeutic Range (TTR) among warfarin users was 42%. The incidence rate of ischemic stroke and death increased with age. The rate of stroke increased from 2 per 1000 person years in patients with CHA2DS2_VASC SCORE of 0, to 58 per 1000 person years in those with a score of 9.ConclusionsIn the present study the prevalence and incidence of AF, stroke, and death were comparable to those reported in Europe and North America. The low use of anticoagulation calls for measures to increase adherence to current treatment recommendations in order to improve outcomes.

show abstract

“…Los datos demuestran incluso frecuencia de accidente cerebrovascular más alta en países en vías de desarrollo: 10,7% a 27%, en comparación con 5% en los países desarrollados (10) Esta variación puede atribuirse a la subutilización de la anticoagulación para la prevención del evento vascular en fibrilación auricular.…”

Section: Cambiar Doacs a Avkunclassified

Anticoagulación Oral: Entre Escila Y Caribdis

S¹

2014

rev cuarzo

View full text Add to dashboard Cite

En este artículo se presentan los resultados de una investigación que tuvo por objeto la exploración de alternativas en anticoagulación oral con impacto en práctica clínica cotidiana, en salud individual y salud pública, a partir de cuatro estudios primarios y un metanálisis que permitió obtener una síntesis de información y presentación de evidencias para la toma de decisiones en práctica clínica en ambientes ambulatorios y hospitalarios.Palabras Clave: práctica clínica, anticoagulación oral, inhibidores anticoagulantes directos. ABSTRACTIn this article the results of an investigation that was aimed at exploring alternative oral anticoagulation impact on everyday clinical practice, individual health and public health, from four primary studies and meta-analysis that provided a synthesis presented information and presentation of evidence for decision-making in clinical practice and hospital outpatient settings. Entre la trombosis y la hemorragia. Situación compleja, semejante a la "vivida" por Ulises, en la Odisea de Homero. Navegar por un estrecho, a un lado del estrecho está un monstruo llamado Escila, feliz de engullir marineros. Por otro lado está Caribdis, un monstruo traga barcos.Ulises debe maniobrar lo suficientemente lejos de Escila para evitar que sus marineros sean devorados, pero no tan cerca de Caribdis para evitar que su barco sea llevado a las profundidades del mar. Ciertamente es una situación extremadamente difícil pero habrá que sortearla a sabiendas de los riesgos, no importa cuál sea la elección, hay riesgos.Durante más de medio siglo, los antagonistas de la vitamina K (AVK) permanecieron como los úni-cos anticoagulantes orales disponibles para uso clínico en diversos desórdenes trombóticos. Desde hace un decenio los "nuevos" anticoagulantes orales (NOACs), actualmente identificados como anticoagulantes orales directos (direct oral anticoagulants (DOACs) representan para pacientes y médicos una alternativa en el tratamiento anticoagulante. La eficacia, farmacocinética predecible, menor posibilidad de interacciones con otros medicamentos o alimentos, además de no requerir monitorización rutinaria, los hace particularmente atractivos; lo cual se refleja en que 3.9 a 6.6 %

show abstract

Review of epidemiology and management of atrial fibrillation in developing countries

Cited by 114 publications

References 74 publications

Management of patients with valvular and non-valvular atrial fibrillation in Poland: Results from Reference Cardiology University Center

Management of patients with valvular and non-valvular atrial fibrillation in Poland: Results from Reference Cardiology University Center

Prospective National Study of the Prevalence, Incidence, Management and Outcome of a Large Contemporary Cohort of Patients With Incident Non‐Valvular Atrial Fibrillation

Anticoagulación Oral: Entre Escila Y Caribdis

Contact Info

Product

Resources

About